- CEO
- Jing Liang Li
- Full Time Employees
- 2,084
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 8 Jinsuo Road Zhengzhou HN China 450001
- IPO Date
- Nov 5, 1999
- Business
- Henan Taloph Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. (600222:CH) is a China-based company principally engaged in the research, development, manufacturing, and sale of pharmaceutical preparations and Chinese herbal medicines; its core products include Shuanghuanglian oral liquid series (concentrated and pediatric variants), Shuangjinlian mixture, Danshen oral liquid, pediatric heat-clearing and cough-relieving oral liquid, pediatric compound chicken gizzard chewable tablets, Huperzine A tablets, pediatric antipyretic oral solution, Shengmai drink, huziyanzong oral liquid, and compound yimu oral liquid, with exclusive offerings among Shuanghuanglian oral liquids, Shuangjinlian mixture, and pediatric compound chicken gizzard chewable tablets. The company operates four primary business segments encompassing pharmaceutical preparations, Chinese medicine tablets, drug research and development services including preclinical and clinical contract research through subsidiaries like Beijing New Leading Pharmaceutical Technology Development Co., Ltd., and pharmaceutical herbal medicine distribution via Henan Tongjuntang Daodi Medicinal Materials Co., Ltd.; it primarily serves hospitals, primary medical institutions, and retail terminals across domestic markets with headquarters in Zhengzhou, Henan Province, where it was founded in 1993 and listed on the Shanghai Stock Exchange in 1999 as the province's first pharmaceutical listing. Recent developments include approval for issuance of 800 million yuan in ultra-short-term financing bonds, changes to its subsidiary Tongjuntang Pharmaceutical Co., Ltd.'s legal representative, board, supervisory personnel, senior management, and business scope in 2025, full liquidation of the third phase of its employee stock ownership plan involving 10,846,100 shares, a 2024 production license change for Dew Drops Root Syrup, and a planned acquisition of stakes in two medicine firms for 516 million yuan announced in 2017, alongside recognition as a Key Leading Enterprise of Henan Province for Agricultural Industrialization in 2024.